Please assess the completion status of the following clinical trial:

Trial Title: Angiotensin-converting Enzyme Inhibitors and Early Sickle Cell Renal Disease in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sickle cell disease (SS, SC, Sb thalassemia, SD Punjab)~* Affiliation to French Health benefits~* Signed informed consent~* Albuminemia / Creatinemia \>= 3 mg / mmol (on 2 samples)~Exclusion Criteria:~* Albuminemia / Creatinemia \> 100 mg / mmol~* Hypersensibility to enalapril~* Angio-oedemas due to a previous treatment by ACE~* idiopathic or hereditary angio-oedemas~* cerebral echo-doppler~* treatment by lithium digoxine~* treatment by other ACE~* congenital galactosemia~* Pregnancy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): None
- 1 (Type: EXPERIMENTAL): Enalapril

Based on this trial design, predict the completion outcome and termination type (if applicable).